Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi is running a global registry called “Atopic ...

Between December 8 and December 10, 2025, SNY faced a series of analyst rating adjustments that tempered investor sentiment.

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysemaAdditional orphan designation ...

Paris, France – December 17, 2025. Sanofi announced today that its Q4 2025 Aide memoire is available on the "Investors" page of the company's website: Fourth quarter & full year 2025 results ...

Sanofi (EURONEXT: SAN) announced Wednesday that its investigational therapy, efdoralprin alfa, has received orphan drug ...

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Two large deals and an acquisition, all totaling about $4.64 billion, are helping close out a strong year. Yarrow Bioscience Inc. cut a potentially $1.36 billion deal with Shanghai Scizeng Medical ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

"Sanofi signs pair of billion-dollar biotech deals to bolster pipeline" was originally created and published by ...